Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Xenon Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ:XENE traded down $0.45 during mid-day trading on Thursday, reaching $38.90. 563,754 shares of the stock were exchanged, compared to its average volume of 388,692. The stock’s 50 day simple moving average is $41.93 and its 200-day simple moving average is $40.47. Xenon Pharmaceuticals Inc. has a one year low of $35.53 and a one year high of $50.99. The company has a market cap of $2.97 billion, a P/E ratio of -13.79 and a beta of 1.19.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the company posted ($0.73) earnings per share. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 641 shares during the period. nVerses Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 487 shares during the last quarter. Quarry LP lifted its stake in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 2,700 shares during the last quarter. Finally, Vestcor Inc bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth about $327,000. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on XENE shares. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. William Blair raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $56.33.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.